Log In
Print
BCIQ
Print
Print this Print this
 

CL-108

  Manage Alerts
Collapse Summary General Information
Company Charleston Laboratories Inc.
DescriptionBilayered tablet containing 12.5 mg immediate-release promethazine, an anti-emetic, with 7.5 mg hydrocodone and 325 mg acetaminophen
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationPain
Indication DetailsTreat moderate to severe acute pain
Regulatory Designation
Partner Daiichi Sankyo Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$650.0M

$100.0M

$550.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today